The Daily Fuckup

The White House’s pharmaceutical proclamation is not one clean tariff wall. Signed on April 2, 2026, it says the administration will impose a 100% ad valorem duty on patented pharmaceuticals and associated ingredients identified in Annex I, but the main tariff treatment is phased in rather than immediate. For companies listed in Annex III, the tariff treatment takes effect on July 31, 2026. For other companies, the later effective date is September 29, 2026. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2026/04/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states/))

The order also leaves generic pharmaceuticals and biosimilars out of the action “at this time,” including purchases for the Strategic API Reserve. That matters because the proclamation is written around patented products and associated ingredients, not the broader drug market as a whole. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2026/04/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states/))

The structure gets even more specific from there. The proclamation sets a 20% duty for patented pharmaceuticals and ingredients made by companies with Commerce-approved plans to onshore production, with that rate scheduled to rise to 100% four years after the date of the proclamation. It also says companies with fully executed agreements, or companies actively negotiating agreements with Commerce and Health and Human Services on MFN pricing and domestic production, can receive no tariffs at all. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2026/04/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states/))

Annex IV is not a second tariff punch so much as a list of HTSUS codes outside the Annex I action. The annex says those codes are subject to a zero rate under the Section 232 pharmaceutical action, and it also says they are not subject to the surcharge from the separate February 20 temporary import surcharge proclamation. In other words, the order uses multiple lanes, not one universal rule. ([whitehouse.gov](https://www.whitehouse.gov/wp-content/uploads/2026/04/Pharmaceuticals-Imports-ANNEXES-I-II-III-IV.pdf))

There are also named exceptions and product-specific treatment for orphan-designated products, certain nuclear and plasma-based therapies, fertility treatments, cell and gene therapies, antibody drug conjugates, some medical countermeasures, and certain animal-health products tied to trade or security frameworks or urgent U.S. health needs. The proclamation also directs Commerce and HHS to continue negotiations and report back within 90 days. ([whitehouse.gov](https://www.whitehouse.gov/wp-content/uploads/2026/04/Pharmaceuticals-Imports-ANNEXES-I-II-III-IV.pdf))

So the practical story is not that Washington drew a single hard line and stopped there. It built a tariff regime with different start dates, different rates, and multiple off-ramps. That may still be a strong signal to drug makers, but the fine print will decide how much of the headline rate actually lands, and on whom. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2026/04/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states/))